Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and Apoptosis
- 1 May 1998
- journal article
- research article
- Published by Elsevier in Experimental Cell Research
- Vol. 241 (1), 96-101
- https://doi.org/10.1006/excr.1998.4018
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- p53 in drug resistance in ovarian cancerThe Lancet, 1997
- p53 and chemosensitivityNature Medicine, 1996
- Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosisNature Medicine, 1996
- Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATMTrends in Biochemical Sciences, 1995
- Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53Annals of Oncology, 1995
- Decreased cytotoxic effects of doxorubicin in a human ovarian cancer‐cell line expressing wild‐type p53 and WAF1/CIP1 genesInternational Journal of Cancer, 1995
- Taxol: A New Drug with Significant Activity as a Salvage Therapy in Advanced Epithelial Ovarian CarcinomaGynecologic Oncology, 1993
- Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.Proceedings of the National Academy of Sciences, 1993
- Wild-type p53 is a cell cycle checkpoint determinant following irradiation.Proceedings of the National Academy of Sciences, 1992
- p53, guardian of the genomeNature, 1992